FDA Expands Bayer’s Hyrnuo (Sevabertinib) to First-Line HER2-Mutant NSCLC

FDA Clears Bayer’s Hyrnuo as a First-Line Option for HER2-Mutated Lung Cancer

The accelerated approval lets patients with HER2-mutant non-small cell lung cancer take sevabertinib right away, without needing to try chemotherapy first.

By iPharmag Editorial Desk · Sep 11, 2026 · 1 min read

Conceptual illustration of a targeted inhibitor binding a HER2 receptor on a lung cancer cell

Conceptual illustration. The FDA expanded Bayer’s Hyrnuo to first-line HER2-mutant lung cancer.

The FDA has expanded the approval of Bayer’s Hyrnuo (sevabertinib) to the first-line treatment of HER2-mutated non-small cell lung cancer (NSCLC) — meaning eligible patients can now receive it as an initial therapy, not only after other treatment has failed.

What changed

Sevabertinib is a kinase inhibitor — a targeted pill — for adults with locally advanced or metastatic non-squamous NSCLC whose tumors carry HER2 (ERBB2) activating mutations, detected by an FDA-authorized test. It previously required patients to have had prior systemic therapy; the FDA (approval dated September 9, 2026) removed that requirement, opening the door to previously untreated patients.

The evidence

The decision, an accelerated approval, rested on the single-arm Phase 1/2 SOHO-01 trial, in which 75% of patients responded (objective response rate; 69 evaluable patients). Because it’s accelerated approval, continued approval may depend on a confirmatory trial verifying clinical benefit.

Why it matters

HER2 mutations drive a subset of lung cancers, and moving an effective targeted therapy earlier in treatment can spare some patients a round of chemotherapy. The move also intensifies competition in HER2-mutant NSCLC. This is regulatory news, not medical advice; treatment choices belong with an oncologist.

Frequently asked questions

What does the expanded approval change?

Patients with HER2-mutated non-small cell lung cancer can now receive Hyrnuo (sevabertinib) as a first-line therapy, without first needing prior systemic treatment such as chemotherapy.

What is an accelerated approval?

A pathway that allows earlier approval based on promising early evidence (here, a 75% response rate in SOHO-01). Continued approval may require a confirmatory trial to verify the drug’s clinical benefit.

This article is for general information only and is not medical advice. Consult a qualified healthcare professional for any medical decisions.

FDA Clears Bayer&rsquo;s Hyrnuo as a First-Line Option for HER2-Mutated Lung Cancer